Article Text

PDF
Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies
  1. A Verma,
  2. F Kilicaslan,
  3. D O Martin,
  4. S Minor,
  5. R Starling,
  6. N F Marrouche,
  7. S Almahammed,
  8. O M Wazni,
  9. S Duggal,
  10. R Zuzek,
  11. H Yamaji,
  12. J Cummings,
  13. M K Chung,
  14. P J Tchou,
  15. A Natale
  1. The Section of Cardiovascular Electrophysiology, Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
  1. Correspondence to:
    Dr Andrea Natale
    Center for Atrial Fibrillation, Cleveland Clinic Foundation, Desk F 15, 9500 Euclid Avenue, Cleveland, OH 44195, USA; natalea{at}ccf.org

Abstract

Objective: To assess prospectively whether preimplantation B-type natriuretic peptide (BNP) and C reactive protein (CRP) concentrations predict future appropriate therapies from an implantable cardioverter-defibrillator (ICD).

Design and setting: Prospective cohort study conducted in a tertiary cardiac care centre.

Methods: 345 consecutive patients undergoing first time ICD implantation were prospectively studied. Serum BNP and CRP concentrations were obtained the day before ICD implantation. Patients were followed up with device interrogation to assess for appropriate shocks or antitachycardia pacing. Inappropriate therapies were excluded. Mean (SD) follow up was 13 (5) months.

Results: Patients had ischaemic (71%), primary dilated (17%), and valvar or other cardiomyopathies (12%). About half (52%) had ICDs implanted for primary prevention. Sixty three (18%) received appropriate ICD therapies. Serum creatinine, β blocker, statin, and angiotensin converting enzyme inhibitor usage did not differ between therapy and no therapy groups. By univariate comparison, ejection fraction (p  =  0.048), not taking amiodarone (p  =  0.033), and BNP concentration (p  =  0.0003) were risk factors for ICD therapy. However, by Cox regression multivariate analysis, only BNP above the 50th centile was a significant predictor (hazard ratio 2.19, 95% confidence interval 1.07 to 4.71, p  =  0.040). Median BNP was 573 ng/l versus 243 ng/l in therapy and no therapy patients, respectively (p  =  0.0003). More patients with BNP above the 50th centile (27% v 10%, p  =  0.006) received ICD therapies.

Conclusions: A single preimplantation BNP concentration determination is independently predictive of ICD therapies in patients with cardiomyopathies undergoing first time ICD implantation. CRP was not independently predictive of ICD therapies when compared with BNP.

  • AVID, antiarrhythmics versus implantable defibrillators
  • BNP, B-type natriuretic peptide
  • CAD, coronary artery disease
  • CHF, congestive heart failure
  • CI, confidence interval
  • CRP, C reactive protein
  • EF, ejection fraction
  • ICD, implantable cardioverter-defibrillator
  • NICM, non-ischaemic dilated cardiomyopathy
  • NYHA, New York Heart Association
  • SCD-HeFT, sudden cardiac death in heart failure trial
  • VF, ventricular fibrillation
  • VT, ventricular tachycardia
  • natriuretic peptide
  • implantable cardioverter defibrillator
  • shock
  • antitachycardia pacing
  • C reactive protein

Statistics from Altmetric.com

Footnotes

  • Published Online First 27 May 2005

  • A Verma is supported by a fellowship award from the Heart and Stroke Foundation of Canada

  • No competing interests to be declared for this study. No financial support was received for this study. No potential conflicts of interest arise from the publication of this manuscript.

  • Ethics approval: This study was conducted under the specific ethics guidelines of our institutional review board at the Cleveland Clinic Foundation.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.